Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration | Zendy

Emir Kobic | Zendy; Christian M Gill | Zendy; A. Brian Mochon | Zendy; Nelson Nicolasora | Zendy; David P. Nicolau | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration

Author(s) -

Emir Kobic,

Christian M Gill,

A. Brian Mochon,

Nelson Nicolasora,

David P. Nicolau

Publication year - 2021

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofab252

Subject(s) - medicine , pharmacokinetics , bacteremia , pseudomonas aeruginosa , intensive care medicine , dosing , pneumonia , renal replacement therapy , antimicrobial , antibiotics , pharmacology , microbiology and biotechnology , genetics , bacteria , biology

Antimicrobial dosing in patients receiving continuous renal replacement therapy is a continued clinical challenge. We describe a case of a patient receiving cefiderocol 2 g intravenously every 8 hours as a 3-hour infusion for a multidrug-resistant Pseudomonas aeruginosa pneumonia and bacteremia while undergoing continuous venovenous hemodiafiltration. The clinical course and cefiderocol pharmacokinetics are described.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research